China's biotechnology industry has seen significant growth, raising concerns among some U.S. lawmakers about the implications for domestic biopharma companies.
In response, these lawmakers are reportedly laying the groundwork for new legislation and regulations aimed at countering the influence of Chinese biopharma firms.
The discussions highlight ongoing tensions and the complexities of managing international competition in the biotech sector.